Private-equity firms Blackstone and TPG agreed to acquire Hologic for $76 a share, plus up to $3 in contingent payments, valuing the diagnostic and med‑tech firm at as much as $18.3 billion. The deal has unanimous board approval and includes participation from sovereign wealth and global financing partners. Buyout investors said they will keep Hologic’s name and headquarters and invest in product innovation and growth of women’s health technologies. The transaction — one of the largest med‑tech buyouts in recent years — will require shareholder and regulatory approvals and includes a limited go‑shop period to solicit higher offers.